Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: The role of the complement system

Neurobiology of Aging

Volumn 17, Issue 5, 1996, Pages 707-716

  Pasinetti, Giulio Maria ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Antiinflammatory drugs; Complement; Inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; COMPLEMENT SYSTEM; HUMAN; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; REVIEW;

EID: 0030250826     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/0197-4580(96)00113-3     Document Type: Article

References (157)

1. 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52:487-501; 1988.
2. 2. Abramson, S. B.; Weissman, G. The mechanisms of action of non-steroidal anti-inflammatory drugs. Arthritis Rheum. 32:1-9; 1989.
3. 3. Aisen, P. S.; Davis, K. L. Inflammatory mechanisms in Alzheimer's disease: Implications for therapy. Am. J. Psychol. 151:1105-1113; 1994.
4. 4. Amatruda, T. T.; Gerard, N.; Gerard, C.; Simon, M. Specific interactions of chemoattractant factor receptors with G-proteins. J. Biol. Chem. 268:10139-10144; 1993.
5. 5. Andersen, K.; Launer, L. J.; Ott, A.; Hoes, A. W.; Bretler, N. M. B.; Hofman, A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam study. Neurology 45: 1441-1445; 1995.
6. 6. Auteri, A.; Saletti, M.; Blardi, P.; DiPerri, T. Action of a new non-steroidal antiinflammatory drug, nimesulide, on activation of the complement system: an in vitro study. Intern. J. Tissue React. 1:217-221; 1988.
7. 7. Bahr, B. A.; Godshall, A. C.; Hall, R. A.; Lynch, G. Mouse telencephalon exhibits an age-related decrease in glutamate (AMPA) receptors but no change in nerve terminal markers. Brain Res. 589: 320-326; 1992.
8. 8. Bancher, C.; Braak, C.; Fisher, P.; Jellinger, K. A. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci. Lett. 162:179-182; 1993.
9. 9. Bertrand, P.; Poirier, J.; Oda, T.; Finch, C. E.; Pasinetti, G. M. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Mol. Brain. Res. 33:174-178; 1995.
10. 10. Bi, X.; Tocco, G.; Baudry, M. Calpain-mediated regulation of AMPA receptors in adult rat brain. Neuroreport 6:61-64; 1994.
11. 11. Breder, C. D.; Smith, W. L.; Raz, A.; Mansferrer, J.; Seibert, K.; Needleman, P.; Saper, C. B. Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brain. J. Comp. Neurol. 322:409-438; 1992.
12. 12. Breitner, J. C. S.; Gau, B. A.; Welsh, K. A.; Plassman, B. L.; McDonald, W. M.; Helms, M. J.; Anthony, J. C. Inverse association of anti-inflammatory treatments and Alzheimer's disease. Initial results of a co-twin control study. Neurology 44:227-232; 1994.
13. 13. Breitner, J. C. S.; Welsh, K. A.; Helms, M. J.; Gaskell, P. C.; Gau, B. A.; Roses, A.D.; Perikak-Vance, M. A.; Saunders, A. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging 16:523-530; 1995.
14. 14. Brugg, B.; Dubreuil, Y. L.; Huber, G.; Wollman, E. E.; Delhaye-Bouchaud, N.; Mariani, J. Inflammatory processes induce β-amyloid precursor protein changes in mouse brain. Proc. Natl Acad. Sci. USA 92:3032-3035; 1995.
15. 15. Casolaro, V.; Meliota, S.; Marino, O.; Patella, V.; de Paulis, A.; Guidi, G.; Marone, G. Nimesulide, a sulfonamide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mast cells. J. Pharmacol. Exp. Ther. 267:1375-1385; 1993.
16. 16. Chang, J. W.; Seiski, D. J.; Coleman, P. D.; O'Banion, M. K. Quantification of the IL-1β induced messages, plasminogen activation inhibithor type-1 and prostaglandin G/H synthase-2 in Alzheimer's disease. Soc. Neurosci. Abstr. 20:1034; 1994.
17. 17. Chang, J. W.; Callahan, L. M.; Chen, W.; Coleman, P. D.; O'Banion, M. K. Localization of inducible prostaglandin G/H synthase-2 (cyclooxygenase-2, PGHS-2) to neurons in Alzheimer's and control human brain. Soc. Neurosci. Abstr. 21:739; 1995.
18. 18. Choi, D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634; 1988.
19. 19. Choi, N. H.; Mazda, T.; Tomita, M. A serum SP40,40 modulates the formation of membrane attack complex of complement on erythrocytes. Mol. Immunol. 26:835-840; 1989.
20. 20. Choi-Miura, N. H.; Ihara, Y.; Fukuchi, K.; Takeda, M.; Nakano, Y.; Tobe, T.; Tomita, M. SP-40,40 is a costituent of Alzheimer's amyloid. Acta Neuropathol. 83:260-264; 1992.
21. 21. Compston, D. A. S.; Scolding, N. J.; Wren, D.; Noble, N. The pathogenesis of demyelinating disease: Insights from cell biology. Trends Neurosci. 14:175-182; 1991.
22. 22. Del Bo, R.; Angeretti, N.; Lucca, E.; De Simoni, M. G.; Forloni, G. Reciprocal control of inflammatory cytokines IL-1 and IL-6 and β-amyloid production in cultures. Neurosci. Lett. 188:70-74; 1995.
23. 23. DeSimoni, M.; Mascarucci, P.; Hogan, S. A.; Johnson, S. A.; Pasinetti, G. M. Genotypic influences on cytokines expression in astrocytes. The role of complement component C5. Soc. Neurosci. Abstr. 21:2109; 1995.
24. 24. Dickson, D.W.; Wertkin, A.; Mattiace, L. A.; Fier, E.; Kress, Y.; Davies, P.; Yen, S. H. Ubiquitin immunoelectron microscopy of dystrophic neurites in cerebellar senile plaques of Alzheimer's disease. Acta Neuropathol. 79:486-493; 1990.
25. 25. Eikelenboom, P.; Stam, F. C. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol. (Berl.) 57:239-242; 1982.
26. 26. Eikelenboom, P.; Stam, F. C. An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer's dementia. Virchows Arch. 47:17-25; 1984.
27. 27. Eikelenboom, P.; Hack, C. E.; Rozemuller, J. M.; Stam, F. C. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch. 56:259-260; 1989.
28. 28. Eikelenboom, P.; Hack, C. E.; Kamphorst, W.; Rozemuller, J. M. Distribution pattern and functional state of complement proteins and alpha 1-antichymotrypsin in cerebral beta/A4 deposits in Alzheimer's disease. Res. Immunol. 143:617-620; 1992.
29. 29. Eikelenboom, P.; Zhan, S. S.; van Gool, W.A.; Allsop, D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol. Sci. 15:447-450; 1994.
30. 30. Farries, T. C.; Atkinson, J. P. Evolution of the complement system. Immunol. Today 12:295-300; 1991.
31. 31. Fraser, D. G.; Regal, J. F. C5a/C5a des-arg-induced increase in blood pressure in the guinea pig: Role of thromboxane. Immunopharmacology 19:59-68; 1990.
32. 32. Fratelli, M.; Galli, G.; Pasinetti, G. M. Role of clusterin in cell adhesion and death mechanisms in P19 embryonic carcinoma cells. Biochem. Biophys. Acta 1311:71-76; 1996.
33. 33. French, L. E.; Wohlwend, A.; Sappino, A. P.; Tschopp, J.; Schifferli, J. A. Human clusterin gene expression is confined to surviving cells in vitro programmed cell death. J. Clin. Invest. 93:877-884; 1994.
34. 34. Finch, C. E. Therapeutic targets in Alzheimer's disease: Suggestion for the NIA. Neurobiol. Aging 15(Suppl. 2):s183-s185; 1994.
35. 35. Games, D.; et al. Alzheimer-type neuropathology in transgenic mice over expressing V717F β-amyloid precursor protein. Nature 373: 523-527; 1995.
36. 36. Garlepp, M. J.; Fritzler, M. J.; Hart, D. A. Differential effect of inflammatory stimuli on murine plasma C4 and factor B concentrations. Clin. Invest. Med. 11:341-346; 1988.
37. 37. Gasque, P.; Fontaine, M.; Morgan, B. P. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cells lines. J. Immunol. 154:4726-4733; 1995.
38. 38. Gerard, N. P.; Gerard, C. The chemotactic receptor for human C5a anaphylatoxin. Science 349:614-617; 1991.
39. 39. Giulian, D.; Vaca, K.; Corpuz, M. Brain glia release factors with opposing actions upon neuronal survival. J. Neurosci. 13:29-37; 1993.
40. 40. Goldsmith, S. K.; Finch, C. E. Study of de novo synthesis of C1q protein in kainic acid treated rat brain. Soc. Neurosci. Abstr. 21:1149; 1995.
41. 41. Haga, S.; Ikeda, K.; Sato, M.; Ishii, T. Synthetic Alzheimer amyloid beta/A4 peptides enhance production of C3 component by cultured microglial cells. Brain Res. 601:88-94; 1993.
42. 42. Hall, E. D.; Andrus, P. K.; Althaus, J. S.; Von Voightlander, P. F. Hydroxyl radical production and lipid peroxidation parallels selective postischemic vulnerability in gerbil brain. J. Neurosci. Res. 34:107-112; 1993.
43. 43. Hartikka, J.; Hefti, F. Development of septal cholinergic neurons in cultur: Plating density and glia cells modulate effects of NGF on survival, fiber growth and expression of trasmitter specific enzymes. J. Neurosci. 8:2967-2985; 1988.
44. 44. Hertting, G.; Seregi, A. Formation and function of eicosanoids in the cerebral nervous system. Ann. NY Acad. Sci. 559:84-99; 1989.
45. ++ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science 252:851-853; 1991.
46. 46. Hugli, T. E. The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a. CRC Crit. Rev. Immunol. 1:321-366; 1981.
47. 47. Ishii, T.; Haga, S. Complement, microglial cells and amyloid fibril formation. Res. Immunol. 143:614-616; 1992.
48. 48. Jenne, D. E.; Tschopp, J. Clusterin the intringuing guises of a widely expressed glycoprotein. Trends Biochem. Sci. 17:154-159; 1992.
49. 49. Jiang, H.; Burdick, D.; Glabe, C. G.; Cotman, C. W.; Tenner, A. J. β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152:5050-5059; 1994.
50. 50. Johnson, S.; Lamphert-Etchells, M.; Pasinetti, G. M.; Rozovsky, I.; Finch, C. E. Complement mRNA in mammalian brain: Responses to Alzheimer's disease and experimental brain lesioning. Neurobiol. Aging. 13:641-648; 1992.
51. 51. Johnson, S. A.; Pasinetti, G. M.; Finch, C. E. Expression of complement C1qB and C4 mRNAs during rat brain development. Dev. Brain Res. 80:163-174; 1995.
52. 52. Johnson, S. A.; Young-Chan, C. S.; Laping, N. J.; Finch, C. E. Perforant path transection induces complement C9 deposition in hippocampus. Exp. Neurol. 138:198-205; 1996.
53. 53. Keinanen, K.; Wisden, W.; Sommer, B.; Werner, P.; Herb, A.; Verdoorn, T. A.; Sakmann, B.; Seeburg, P. H. A family of AMPA-selective glutamate receptors. Science 249:556-560; 1990.
54. 54. Kopp, E.; Gosh, S. Inhibition of NF-kB by sodium salycilate and aspirin. Science 265:956-959; 1994.
55. 55. Kounnas, M. Z.; Loukinova, E. B.; Stefansson, S.; Harmony, J. A. K.; Brewer, B. H.; Strickland, D. K.; Argraves, S. Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. J. Biol. Chem. 270:13070-13075; 1995.
56. 56. Kounnas, M. Z.; Moir, R. D.; Rebeck, G. W.; Bush, A. I.; Argraves, W. S.; Tanzi, R. E.; Hyman, B. T.; Strikland, D. K. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted β-amyloid precursor protein and mediated its degradation. Cell 82: 331-340; 1995.
57. 57. Lampert-Etchells, M.; McNeill, T. H.; Laping, N. J.; Zarow, C.; Finch, C. E.; May, P. C. Sulfated glycoprotein-2 is increased in rat hippocampus following entorhinal cortex lesioning. Brain Res. 563: 101-106; 1991.
58. 58. Lampert-Etchells, M.; Pasinetti, G. M.; Finch, C. E.; Johnson, S. A. Regional localization of cells containing C1q and C4 mRNAs in the frontal cortex during Alzheimer's disease. Neurodegeneration 2:111-121; 1993.
59. 59. Laping, N.J.; Morgan, T. E.; Nichols, N. R.; Rozovsky, I.; Young-Chan, C. S.; Zarow, C.; Finch, C. E. TGFβ-1 induces neuronal and astrocyte genes: Tubulin alpha-1, glial fibrillary acidic protein and clusterin. Neuroscience 58:563-572; 1994.
60. 60. Lappin, D. F.; Whaley, K. Modulation of complement gene expression by glucocorticoids. Biochem. J. 280:117-123; 1991.
61. 61. Linder, E.; Lehto, V. P.; Stenman, S. Activation of complement by cytoskeletal intermediate filaments. Nature 278:280; 1979.
62. 62. Liu, L.; Tornqvist, E.; Mattsson, P.; Eriksson, N. P.; Persson, J. K. E.; Morgan, B. P.; Aldskogius, H.; Svensson, M. Complement and clusterin in the spinal cord dorsal horn and gracile nucleus following sciatic nerve injury in the adult rat. Neuroscience 68:167-179; 1995.
63. 63. Lu, X.; Richardson, P. Inflammation near the nerve cell body enhances axonal regeneration. J. Neurosci. 11:972-979; 1991.
64. 64. Lucca, U.; Tettamanti, M.; Forloni, G.; Spagnoli, A. Nonsteroidal anti-inflammatory drug use in Alzheimer's disease. Biol. Psychiatry 36:854-856; 1994.
65. 65. Lue, L. H.; Rogers, J. Full complement activation fails in diffuse plaques of the Alzheimer's disease cerebellum. Dementia 3:308-313; 1992.
66. 66. Masliah, E.; Mallroy, M.; Ge, N.; Saitoh, T. Protein kinases and growth associated proteins in plaque formation in Alzheimer's disease. Rev. Neurosci. 3:99-107; 1992.
67. 67. Masliah, E.; Cole, G. M.; Hansen, L. A.; Mallory, M.; Albright, T.; Terry, R. D.; Saitoh, T. Protein kinase C alteration is an early biochemical marker in Alzheimer's disease. J. Neurosci. 11:2759-2767; 1991.
68. 68. Massicotte, G.; Kassler, M.; Lynch, G.; Baudry, M. N-Methyl-D-Aspartate and quisqualate/AMPA receptors: Differential regulation by phospholipase C treatment. Mol. Pharmacol. 32:278-285; 1990.
69. 69. May, P. C.; Finch, C. E. Sulfated glycoprotein 2: New relationships of this multifunctional protein to neurodegeneration. Trends Neurosci. 15:391-396; 1992.
70. 70. Meda, L.; Cassatella, M. A.; Szendrei, G. I.; Otvos, L.; Baron, P.; Villalba, M.; Ferrari, D.; Rossi, F. Activation of microglial cells by β-amyloid protein and interferon. Nature 374:647-650; 1995.
71. 71. McGeer, P. L.; Akiyama, H.; Itagaki, S.; McGeer, E. G. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107:341-346; 1989.
72. 72. McGeer, P. L.; Akiyama, H.; Itagaki, S.; McGeer, E. G. Immune system response in Alzheimer's disease. Can. J. Neurol. Sci. 16:516-527; 1989
73. 73. McGeer, P. L.; Walker, D. G.; Akiyama, H.; Kawamata, T.; Guan, A. L.; Parker, C. J.; Okada, N.; McGeer, E. G. Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Mol. Brain Res. 544:315-319; 1991.
74. 74. McGeer, P. L.; Kawamata, T.; Walker, D. G. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 579:337-341; 1992.
75. 75. Monk, P.; Bank, P. The role of protein kinase C activation and inositol phosphate production in the regulation of cell-surface expression of MAC-1 by complement fragment C5a. Biochem. Biophys. Acta 1092:251-255; 1991.
76. 76. Mori, S.; Sternberger, N. H.; Herman, M. M.; Sternberger, L. A. Leakage and neuronal uptake of serum protein in aged and Alzheimer brains. A postmortem phenomenon with antemortem etiology. Lab. Invest. 64:345-351; 1991.
77. 77. Morganti-Kossmann, M. C.; Kossmann, T.; Brandes, M. E.; Mergenhagen, S. E.; Wahl, S. M. Autocrine and paracrine regulation of astrocyte functions by TGF-β. J. Neuroimmunol. 39:163-174; 1992.
78. 78. Namba, Y.; Tomonaga, M.; Kawasaki, H.; Otomo, E.; Ikeda, K.; Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and Kuru plaque amyloid in Creutzfeldt-Jacob disease Brain Res. 541:163-166; 1991.
79. 79. Oda, T.; Pasinetti, G. M.; Osterburg, H. H.; Anderson, C.; Johnson, S. A.; Finch, C. E. Purification and characterization of brain clusterin. Biochem. Biophys. Res. Commun. 204:1131-1136; 1994.
80. 80. Oda, T.; Lehrer-Graiwer, J.; Finch, C. E.; Pasinetti, G. M. Complement and β-amyloid (Aβ) neurotoxicity in vitro: A model for Alzheimer's disease. Alzheimer's Res. 1:29-34; 1995.
81. 81. Oda, T.; Wais, P.; Osterburg, H. H.; Johnson, S. A.; Pasinetti, G. M.; Morgan, T. E.; Rozovski, I.; Stine, W. B.; Snyder, S. W.; Holzman, T. F.; Krafft, G. A.; Finch, C. E. Clusterin (apoJ) alters the aggregation of amyloid β-peptide (Aβ1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress. Exp. Neurol. 136:22-31; 1995.
82. 82. Okusawa, S.; Yancey, K. B.; VanDerMeer, J. W. M.; Endres, S.; Lonneman, G.; Hefter, K.; Frank, M. M.; Burke, J. F.; Dinarello, C. A.; Gelfand, C. A. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin-1β and interleukin-1α. J. Exp. Med. 168:443-448; 1988.
83. 83. Oliver, M. W.; Baudry, M.; Lynch, G. The protease inhibitor leupeptin interferes with the development of LTP in hippocampal slices. Brain Res. 505:233-238; 1989.
84. 84. O'Sullivan, M. G.; Chilton, F. H.; Huggins, E. M.; McCall, C. E. Lipopolysaccaride priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase. J. Biol. Chem. 267:14547-14550; 1992.
85. 85. Pasinetti, G. M.; Cheng, H. W.; Reinhard, J. F.; Finch, C.; McNeill, T. Molecular and morphological correlates following neuronal deafferentation: A cortico-striatal model. Adv. Exp. Med. Biol. 296:249-255; 1991.
86. 86. Pasinetti, G. M.; Johnson, S. A.; Lampert-Ethelles, M.; Finch, C. E. Complement mRNA markers and responses to striatal deafferentation. Exp, Neurol. 118:117-126; 1992.
87. 87. Pasinetti, G. M.; Kohama, S.; Reinhard, J. F., Jr.; Cheng, H. W.; McNeill, T. H.; Finch, C. E. Striatal responses to decortication. (I), dopaminergic and astrocytic activity. Brain Res. 567:253-259; 1992.
88. 88. Pasinetti, G. M.; Cheng, H. W.; Lampert-Etchells, M.: Morgan, D. G.; McNeill, T. H.; Finch, C. E. Astrocytic specific mRNA responses to striatal deafferentation in rat. Neuroscience 53:199-211; 1993.
89. 89. Pasinetti, G. M.; Nichols, N.; Finch, C. E. Transforming growth factor β1 (TGF-β1) and fibronectin mRNA in rat brain: Response to injury and cell-type localization. Neuroscience 54:893-907; 1993.
90. 90. Pasinetti, G. M.; Johnson, S. A.; Finch, C. E. Clusterin (SGP-2): A multifunctional glycoprotein with selective regional expression in astrocytes and neurons of adult rat brain. J. Comp. Neurol. 339:387-400; 1994.
91. 91. Pasinetti, G. M.; Oda, T.; Johnson, S. A.; Finch, C. E. Brain clusterin (ApoJ) and its interaction with β-amyloid (Aβ). Soc. Neurosci. Abstr. 20:1642; 1994.
92. 92. Pasinetti, G. M.; Kounnas, M. Z.; Morgan, T. E.; Argraves, W. S.; Finch, C. E. Regulation of the low density lipoprotein receptor family members gp330 and LRP: An immunocytochemical study of experimental lesion models of Alzheimer disease. (submitted).
93. 93. Pasinetti, G. M.; Finch, C. E. Sulfated glycoprotein 2 (SGP-2) mRNA is expressed in rat striatal astrocytes following ibotenic acid lesions. Neurosci. Lett. 130:1-4; 1991.
94. 94. Paul, M. S.; Aegerter, M.; O'Brien, S.; Kurtz, C. B.; Weis, J. H. The murine complement receptor gene family. Analysis of mCRY gene products and their homology to human CR1. J. Immunol. 142:582-589; 1989.
95. 95. Pellegrini-Giampietro, D. E.; Zukin, S. R.; Bennett, M. V. L.; Cho, S.; Pulsinelli, W. A. Switch in glutamate receptor subunit gene expression in CA1 subfield of hippocampus following global ischemia in rats. Proc. Natl. Acad. Sci. USA 89:10499-10503; 1992.
96. 96. Perret, J.; Raspe, E.; Vassart, G.; Parmentier, M. Cloning and functional expression of the canine anaphylotoxin C5a receptor. Biochem. J. 288:911-917; 1992.
97. 97. Piddlesden, S. J.; Morgan, P. Killing of rat glial cells by complement: Deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis. J. Immunol. 4:169-176; 1993.
98. 98. Piddlesden, S.; Lassmann, H.; Laffafian, I.; Morgan, B. P.; Linington, C. Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation. Clin. Exp. Immunol. 83:245-250; 1991.
99. 99. Raij, L.; Dalmasso, A. P.; Staley, N. A.; Fish, A. J. Renal injury in DOCA-salt sensitive hypertensive C5-sufficient and C5-deficient mice. Kidney Int. 36:582-592; 1989.
100. 100. Reife, R. A.; Loutis, N.; Watson, W. C.; Hasty, K. A.; Stuart, J. M. SWR mice are resistant to collagen-induced arthritis but produce potentially arthritogenic antibodies. Arthritis Rheum. 34:776-781; 1991.
101. 101. Reiter, Y.; Ciobotariu, A.; Fishelson, Z. Sublytic complement attack protect tumor cells from lytic doses of antibody and complement. Eur. J. Immunol. 22:1207-1213; 1992.
102. 102. Reiter, Y.; Fishelson, Z. Complement membrane attack complexes induce in human leukemic cells rapid expression of large proteins (L-CIP). Mol. Immunol. 29:771-781; 1992.
103. 103. Rich, J. B.; Rasmusson, D. X.; Folstein, M. F.; Carson, K. A.; Kavas, C.; Brandt, J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45:51-55; 1995.
104. 104. Rogers, J.; Cooper, N. R.; Webster, S.; Schultz, J.; McGeer, P. L.; Styren, S.D.; Civin, W. H.; Brachova, L.; Bradt, B.; Ward, P.; Lieberburg, I. Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 89:10016-10020; 1992.
105. 105. Rogers, J.; Kirby, L. C.; Hempleman, S. R.; Berry, D. L.; McGeer, P. L.; Kaszniak, A. W.; Zalinski, J.; Cofield, M.; Mansukhani, L.; Willson, P.; Kogan, F. Clinical trial of Indomethacin in Alzheimer's disease. Neurology 43:1609-1611; 1993.
106. 106. Rother, K.; Till, G. O., eds. The complement system. Berlin: Springer Verlag; 1988.
107. 107. Rothstein, J. L.; Lint, T. F.; Schreiber, H. Tumor necrosis factor/ cachetin. Induction of hemorragic necrosis in normal tissue requires the fifth component of complement (C5) J. Exp. Med. 168:2007-2021; 1988.
108. 108. Rozemuller, J. M.; Eikelenboom, P.; Kamphorst, W.; Stam, F. C. Lack of evidence for dysfunction of the blood-brain barrier in Alzheimer's disease: An immunohistochemical study. Neurobiol. Aging 9:383-391; 1988.
109. 109. Rozemuller, J. M.; Eikelenboom, P.; Stam, F, C.; Beyreuther, K.; Masters. C. L. A4 protein in Alzheimer's disease: Primary and secondary cellular events in extracellular amyloid deposition. J. Neuropathol. Exp. Neurol. 48:674-691; 1989.
110. 110. Rozemuller, J. M.; Eikelenboom, P.; Pals, S. T.; Stam, F. C. Microglial cells around plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci. Lett. 101:288-292; 1989.
111. 111. Rozemuller, J. M.; Stam, F. C.; Eikelenboom, P. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease. Neurosci. Lett. 119:75-78; 1990.
112. 112. Rozemuller, J. M.; van-der-Valk, P.; Eikelenboom, P. Activated microglia and cerebral amyloid deposits in Alzheimer's disease. Res. Immunol. 143:646-649; 1992.
113. 113. Rozovski, I.; Morgan, T. E.; Willoughbly, D. A.; Dugich-Djordevich, M. M.; Pasinetti, M. M.; Johnson, S. A.; Finch, C. E. Selective expression of clusterin (SGP-2) and complement C1qB and C4 during responses to neurodegeneration in vivo and in vitro. Neuroscience 62:741-758; 1994.
114. 114. Rubin, J.; Titus, L.; Nanes, M. S. Regulation of complement C5a receptor expression in U937 cells by phorbol ester. J. Leukoc. Biol. 50:502-508; 1991.
115. 115. Schindler, R.; Lonneman, G.; Stanley, S.; Koch, K.; Dinarello, C. Transcription not synthesis, of interleukin-1 and tumor becrosis factor by complement. Kidney Int. 37:85-93; 1990.
116. 116. Schriber, S.S.; Tocco, G.; Najm, I.; Baudry, M. Seizure activity causes a rapid increase in sulfated glycoprotein-2 messenger RNA in the adult but not the neonatal rat brain. Neurosci. Lett. 153:17-20; 1993.
117. 117. Schupf, N.; Williams, C.; Berkman, A.; Cattell, W.; Kerper, L. Binding specificity and presynaptic action of anaphylatoxin C5a in rat brain. Brain Behav. Immun. 3:28-38; 1989.
118. 118. Schultz, J. J.; Schaller, J.; McKinley, M.; Bradt, B.; Cooper, N.; May, P.; Rogers, J. Enhanced cytotoxicity of amyloid beta-peptide by a complement dependent mechanism. Neurosci. Lett. 175:99-102; 1994.
119. 119. Seifert, P. S.; Hansson, G. K. Decay-accelerator factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions. J. Clin. Inv. 84:597-604; 1989.
120. 120. Shearman, M. S.; Ragan, C. I.; Iversen, L. Inhibition of PC-12 cell redox activity is a specific, early indicator of the mechanism of β-amyloid mediated cell death Proc. Natl. Acad. Sci. USA 91:1470-1474; 1994.
121. 121. Shen, Y.; Halperin, J.; Lee, C. E. Complement-mediated neurotoxicity is regulated by homologous restriction. Brain Res. 671:282-292; 1995.
122. 122. Shimizu, T.; Wolfe, L. S. Arachidonic acid cascade and signal transduction. J. Neurochem. 55:1-15; 1990.
123. 123. Shin, M. L.; Koski, C. L. The complement system in demyelination. In: Martenson, R. E., ed. Myelin biology and chemistry. Boca Raton, FL; CRC Press; 1992:801-831.
124. 124. Siciliano, S.; Rollins, T. E.; DeMartino, J.; Konteatis, Z.; Malkowitz, L.; Van Riper, G.; Bondy, S.; Rosen, H.; Spriger, M. Two-site binding of C5a by its receptor: An alternative binding paradigm for G protein-coupled receptors. Proc. Natl. Acad. Sci. USA 91:1214-1218; 1994.
125. 125. Spinella, D. G.; Jeffers, J. R.; Reiffe, R. A.; Stuart, J. M. The role of C5 and T-cell receptor Vb genes in susceptibility to collagen-induced arthritis. Immunogenetics 34:23-27; 1991.
126. 126. Steward, O.; Vinsant, S. L.; Davis, L. The process of reinnervation in the dentate gyrus of adult rats: An ultrastructural study of changes in presynaptic terminals as result of sprouting. J. Comp. Neurol. 267: 203-210; 1988.
127. 127. Styren, S. D.; Civin, W. H.; Rogers, J. Molecular, cellular and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain. Exp. Neurol. 110:93-104; 1990.
128. 128. Streit, W. J. An improved staining method for rat microglial cells using the lectin from Griffonia simplicifolia (GSA I-B4). J. Histochem. Cytochem. 38:1683-1686; 1990.
129. 129. Sun, X.; Hsueh, W. Platelet-activating factor produces shock, in vivo complement activation, and tissue injury in mice J. Immunol, 147: 509-514; 1991.
130. 130. Svenson, M.; Liu, L.; Mattson, P.; Morgan, B. P.; Aldskogius, P. Evidence for activation of the terminal pathway of complement and upregulation of sulfated glycoprotein (SGP-2) in the hypoglossal nucleus following peripheral nerve injury. Mol. Chem. Neuropathol. 24:53-67; 1995.
131. 131. Tanabe, Y.; Masu, M.; Ishii, T.; Shigemoto, R.; Nakanishi, S. A family of metabotropic glutamate receptors. Neuron 8:169-179; 1992.
132. 132. Terry, R. D.; Gonatas, N. K.; Weiss, M. Ultrastructural studies in Alzheimer's presenile dementia. Am. J. Pathol. 44:269-297; 1964.
133. 133. Tocco, G.; Devgan, K. K.; Hauge, S.A.; Weiss, C.; Baudry, M.; Thompson, R. F. Classical conditioning selectively increases AMPA receptor binding in the rabbit hippocampus. Brain Res. 559:331-336; 1991.
134. 134. Tocco, G.; Massicotte, G.; Standley, S.; Thompson, R. F.; Baudry, M. Effect of temperature and calcium on the binding properties of the AMPA receptor in frozen rat brain sections. Eur. J. Neurosci. 4:1093-1103; 1992.
135. 135. Tocco, G.; Massicotte, G.; Standley, S.; Thompson, R. F.; Baudry, M. Phospholipase A2-induced changes in the affinity of the AMPA receptor: An autoradiographic study. Neuroreport 3:515-518; 1992.
136. 136. Tocco, G.; Musleh, W.; Pasinetti, G. M. Inflammatory mechanisms of neurodegeneration. The role of the complement derived anaphylatoxin C5a. Soc. Neurosci. Abstr. 21:1722; 1995.
137. 137. Tocco, G.; Musleh, W.; Baudry, M.; Pasinetti, G. M. Complement C5 in neurodegeneration (2). Differential regulation of AMPA receptors in C5 deficient mice. (submitted).
138. 138. Vanderklish, P.; Kessler, M.; Hall, R.; Bahr, B.; Sumikawa, K.; Lynch, G. The AMPA/quisqualate receptor is a substrate for calpain. Soc. Neurosci. Abstr. 17:613; 1991.
139. 139. Veerhuis, R.; van der Valk, P.; Janssen, I.; Zhan, S. S.; Van Nostrand, W. E.; Eikelenboom, P. Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3. Virchows Arch. 426:603-610; 1995.
140. 140. Veerhuis, R.; Janssen, I.; Hack, C. E.; Eikelenboom, P. Early complement components in Alzheimer's disease. Acta Neuropathol. 91:53-60; 1996.
141. 141. Walker, D. G.; McGeer, P. L. Complement gene expression in human brain: Comparison between normal and Alzheimer disease cases. Mol. Brain Res. 14:109-116; 1992.
142. 142. Walker, D. G.; Yasuhara, O.; Patston, P. A.; McGeer, E. G.; McGeer, P. L. Complement C1 inhibithor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res. 675:75-82; 1995.
143. 143. Weissmann, H. F.; Bartow, T.; Leppo, M. K.; Marsh, H. C., Jr.; Carson, G. R.; Concino, M. F.; Boyle, M. P.; Roux, K. H.; Weisfeldt, M. R.; Fearon, D. T. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing postischemic myocardial inflammation and necrosis. Science 249:146-151; 1990.
144. 144. Weissmann, G.; Korchack, H.; Ludewig, R.; Edelson, H.; Haines, K.; Levin, R. I.; Herman, R.; Rider, L.; Kimmel, S.; Abramson, S. Non-steroidal anti-inflammatory drugs: How do they work? Eur. J. Rheumatol. Inflamm. 8:6-17; 1987.
145. 145. Widmer, H. R.; Ohsawa, F.; Knusel, B.; Hefti, F. Down-regulation of phospatidylinositol response to BDNF and NT3 in cultures of cortical neurons. Brain Res. 614:325-334; 1993.
146. 146. Williams, C.; Schupf, N.; Hugli, T. Anaphylatoxin C5a modulation of an alpha-adrenergic receptor system in the rat hypothalamus. J. Neuroimmunol. 9:29-40; 1985.
147. 147. Wong, P.; Taillefer, D.; Lakins, J.; Pineault, J.; Chader, G.; Tenniswood, M. Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration. Eur. J. Biochem. 221:917-925; 1995.
148. 148. Wong, P. T.; McGeer, P. L.; McGeer, E. G. Decreased prostaglandin synthesis in postmortem cerebral cortex from patients with Alzheimer's disease. Neurochem. Int. 21:197-202; 1992.
149. 149. Wood, A.; Wing, M. C.; Benham, C. D.; Compston, D. A. S. Specific induction of intracellular calcium oscillation by complement membrane attack on oligodendroglia. J. Neurosci. 13:3319-3332; 1993.
150. 150. Wu, E.; Brosnan, C. F.; Raine, C. SP-40,40 immunoreactivity in inflammatory CNS lesions displaying astrocyte/oligodendrocyte interactions. J. Neuropathol. Exp. Neurol. 52:129-134; 1993.
151. 151. Yamada, T.; Akiyama, H.; McGeer, P. L. Complement-activated oligodendroglia: A new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d. Neurosci. Lett. 112:161-166; 1990.
152. 152. Yamaguki, H.; Hirai, S.; Morimatso, M.; Shoji, M.; Ihara, Y. A variety of cerebral amyloid deposits in the brains of Alzheimer-type dementia demonstrated by beta-protein immunostaining. Acta Neuropathol. 76:541-549; 1988.
153. 153. Yamagata, K.; Andreasson, K. L.; Kaufman, W. E.; Barnes, C. A.; Worley, P. F. Expression of a mitogen inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids. Neuron 11:371-386; 1993
154. 154. Yancey, K. B. Biological properties of Human C5a: Selected in vitro and in vivo Studies. Clin. Exp. Immunol. 71:207-210; 1988.
155. 155. Yao, J.; Harvath, L.; Gilbert, D. L.; Colton, C. A. Chemotaxis by a CNS macrophage, the microglia. J. Neurosci. Res. 27:36-42; 1990.
156. 156. Zhan, S. S.; Veerhuis, R.; Janssen, I.; Kamphorst, W.; Eikelenboom, P. Immunohistochemical distribution of the inhibitors of the terminal complement complex in Alzheimer's disease. Neurodegeneration 3: 111-117; 1994.
157. 157. Zurier, R. B. Prostaglandins, leukotrienes and related compounds. In: Kelley, W. N., ed. Textbook of rheumatology. Philadelphia, PA: W. B. Saunders; 1994:201-212.